Skip to main content
Apt Medical Inc. logo

Apt Medical Inc. — Investor Relations & Filings

Ticker · 688617 ISIN · CNE100004C45 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2024-04-29 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688617

About Apt Medical Inc.

https://www.aptmed.com/

Apt Medical Inc. is a specialized developer and manufacturer of advanced medical devices for minimally invasive vascular interventions. The company focuses on the fields of electrophysiology, interventional cardiology, and peripheral vascular procedures. Its product portfolio includes diagnostic and ablation catheters, steerable sheaths, guide wires, microcatheters, and balloon catheters designed for complex cardiovascular treatments. Apt Medical emphasizes research and development to provide high-precision tools for clinicians, aiming to improve procedural outcomes in the treatment of cardiac arrhythmias and vascular diseases. The company serves a global market, providing integrated solutions for interventional procedures through a commitment to technological innovation and quality manufacturing standards.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于深圳惠泰医疗器械股份有限公司2024年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2024 second extraordinary general meeting (临时股东大会) of Shenzhen Huitai Medical Devices Co., Ltd. It details the legal compliance of the meeting's call, attendance, and voting process, and confirms the validity of the resolutions passed. The document is not a financial report, earnings release, or management discussion, but a legal opinion on the shareholder meeting process and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms their legality and validity.
2024-04-29 Chinese
2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on shareholder information. The report explicitly states it is unaudited and covers the first quarter of 2024. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is over 14,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. Q1 2024
2024-04-25 Chinese
关于自愿披露取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (618 characters) from Shenzhen Huitai Medical Devices Co., Ltd. regarding the voluntary disclosure of obtaining a medical device registration certificate. It includes product information, impact on the company, and risk warnings. There is no financial data, no detailed report, no regulatory certification, or voting results. It is an announcement about a company event related to product registration, not a financial report or management change. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-04-19 Chinese
2024年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the 2024 second extraordinary shareholders' meeting of Shenzhen Huitai Medical Devices Co., Ltd. It contains detailed meeting notices, agenda, and multiple proposals related to amendments of company bylaws, nomination of board and supervisory candidates, and other governance matters. The content is focused on the preparation and information for a shareholders' meeting rather than the meeting minutes or voting results. It is a comprehensive set of meeting materials provided to shareholders ahead of the meeting. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or other shareholders' meetings. The document is lengthy (over 13,000 characters) and contains detailed agenda and proposals, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the correct classification is AGM Information (AGM-R).
2024-04-19 Chinese
中信证券股份有限公司关于深圳惠泰医疗器械股份有限公司2023年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导跟踪报告" (2023 Annual Continuous Supervision Tracking Report) issued by the sponsor (中信证券股份有限公司) for 深圳惠泰医疗器械股份有限公司. It references regulatory frameworks related to securities issuance and listing supervision, including the Shanghai Stock Exchange Sci-Tech Innovation Board rules. The report details the sponsor's continuous supervision activities over the company during 2023, including review of governance, financials, internal controls, risk factors, R&D progress, fundraising usage, and shareholding changes. It includes detailed financial data for 2023 and 2022, risk disclosures, and operational updates. The document is comprehensive and substantive, not a brief announcement or certification. It is not a full annual report (10-K) but a specific continuous supervision report by the sponsor as required by regulatory rules for listed companies. This type of document is best classified as an Audit Report / Information (AR) because it contains audit-related findings, internal control evaluations, and sponsor's supervisory opinions, distinct from a full annual report or earnings release. The length and content confirm it is a full report, not an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-18 Chinese
中信证券股份有限公司关于深圳惠泰医疗器械股份有限公司2023年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导工作现场检查报告" which translates to "2023 Annual Continuous Supervision On-site Inspection Report" by the sponsor (中信证券股份有限公司) for the listed company 深圳惠泰医疗器械股份有限公司. The content details the sponsor's on-site inspection of the company's governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, and operational status during the continuous supervision period in 2023. It includes findings, opinions, and recommendations but does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a standalone audit/inspection report related to regulatory continuous supervision and internal control verification. The document length is 3723 characters, which is relatively short but contains substantive inspection content rather than just an announcement or certification. Therefore, it fits best under Audit Report / Information (AR). FY 2023
2024-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.